Search results for " Mark"

showing 10 items of 4118 documents

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the Europe…

2020

Background Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in the FDA drug label and a pharmacogenetic guideline. The aim of this cross-sectional cohort study was to confirm the genetic associations in a large pan-European population and to evaluate the diagnostic accuracy of the genetic…

0301 basic medicineOncologyMaleCancer ResearchCandidate genePharmacogenomic VariantsCancer survivorsCHILDRENAnti-neoplastic drugsVARIANTSOCT2Carboplatin0302 clinical medicineHearingRisk FactorsNeoplasmsTPMTHearing / drug effectsProspective StudiesAge of OnsetChild610 Medicine & healthPREDICTORSmedia_commonHearing Loss Sensorineural / physiopathologyeducation.field_of_studyddc:618Thiopurine methyltransferasebiologycarboplatin [Cisplatin]Neoplasms / drug therapyOrganic Cation Transporter 2EuropeOncologyCisplatin: carboplatinCisplatin / adverse effects030220 oncology & carcinogenesisChild PreschoolOrganic Cation Transporter 2 / geneticsFemaleSENSITIVITYChildhood cancer360 Social problems & social servicesCohort studyDrug-induced ototoxicitymedicine.medical_specialtyINDUCED HEARING-LOSSAdolescentMulticenter cohort studyHearing Loss SensorineuralPopulationAdverse drug reactionAntineoplastic AgentsPolymorphism Single NucleotideRisk AssessmentHearing Loss Sensorineural / chemically inducedCarboplatin / adverse effects03 medical and health sciencesACYP2OtotoxicitySDG 3 - Good Health and Well-beingInternal medicinemedicineGenetic predispositionmedia_common.cataloged_instanceHumansGenetic Predisposition to DiseaseCISPLATIN-INDUCED OTOTOXICITYEuropean unioneducationGenetic Association StudiesGenetic associationRetrospective Studiesbusiness.industryAntineoplastic Agents / adverse effectsInfant NewbornInfantOdds ratioGuidelinemedicine.diseaseOtotoxicityCOMTPharmacogenomic Testing030104 developmental biologyCross-Sectional StudiesPharmacogeneticsbiology.proteinGenetic markersHearing Loss Sensorineural / geneticsCisplatinbusinessPharmacogenetics
researchProduct

Polymorphism of the Transcription Factor 7-Like 2 Gene (TCF7L2) Interacts with Obesity on Type-2 Diabetes in the PREDIMED Study Emphasizing the Heter…

2016

Nutrigenetic studies analyzing gene-diet interactions of the TCF7L2-rs7903146 C > T polymorphism on type-2 diabetes (T2D) have shown controversial results. A reason contributing to this may be the additional modulation by obesity. Moreover, TCF7L2-rs7903146 is one of the most influential variants in T2D-genetic risk scores (GRS). Therefore, to increase the predictive value (PV) of GRS it is necessary to first see whether the included polymorphisms have heterogeneous effects. We comprehensively investigated gene-obesity interactions between the TCF7L2-rs7903146 C > T polymorphism on T2D (prevalence and incidence) and analyzed other T2D-polymorphisms in a sub-sample. We studied 7018 PREDIMED …

0301 basic medicineOncologyMaleobesityendocrine system diseasesType 2 diabetestype-2 diabetesTranscription Factor 7-Like 2Dieta mediterrània0302 clinical medicineNutrigenomicsRisk FactorsPrevalenceTCF7L2-predictive valueDiseaseLongitudinal StudiesProspective StudiesGenetic riskGeneticsAged 80 and overINSULIN-RESISTANCEBioquímica y tecnologíaNutrition and DieteticsDiabetisIncidenceMiddle AgedTraitsMEDITERRANEAN DIETBiochemistry and technologyObesitatTRIALFemalelcsh:Nutrition. Foods and food supplyTranscription Factor 7-Like 2 ProteinAdultGenetic Markersmedicine.medical_specialtyendocrine systemPopulationBODY-FATlcsh:TX341-641030209 endocrinology & metabolismMASSBioquímica i biotecnologiaArticleAssociation03 medical and health sciencesGenetic HeterogeneityPredictive Value of TestsInternal medicineDiabetes mellitusmedicineHumansGenetic Predisposition to DiseaseGeneAgedPolymorphism Geneticbusiness.industryCommon variantsPreventionnutritional and metabolic diseasesGenetic VariationPREDIMED studymedicine.disease2072-6643WeightPredimedObesityTCF7L2TCF7L2; type-2 diabetes; obesity; T2D-genetic risk scores; TCF7L2-predictive value; PREDIMED study030104 developmental biologyDiabetes Mellitus Type 2Susceptibility locibusinessTCF7L2T2D-genetic risk scoresFood Science
researchProduct

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

2017

Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the a…

0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesmedicine.medical_treatment[SDV]Life Sciences [q-bio]Immunologybtn3apancreatic ductal adenocarcinomalcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicineImmunology and AllergyComputingMilieux_MISCELLANEOUSbusiness.industrycd277Aggressive cancerCancerPrognosis MarkerImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensbutyrophilin 3 adigestive system diseases3. Good health[SDV] Life Sciences [q-bio]030104 developmental biologyOncology030220 oncology & carcinogenesisimmunotherapybusinesslcsh:RC581-607Research Article
researchProduct

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

2020

Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6-two lymphocyte surface markers involved in the fine tuning of TCR signaling-as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC).; Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC.; Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, P=0.…

0301 basic medicineOncologymedicine.medical_specialtyLymphocytenon-small cell lung cancer (NSCLC)03 medical and health sciences0302 clinical medicineInternal medicinemedicinemelanomaLung cancerimmune checkpointSurvival analysisbusiness.industryMelanomaMarcadors tumoralsBiochemical markersCD6medicine.diseaseImmune checkpointCD5non-small cell lung cancer (NSCLC)030104 developmental biologymedicine.anatomical_structureReal-time polymerase chain reactionOncology030220 oncology & carcinogenesisTumor markersMarcadors bioquímicsCàncer de pulmóOriginal ArticleCD5Lung cancerbusiness
researchProduct

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours

2017

Distinguishing between follicular thyroid cancer (FTC) and follicular thyroid adenoma (FTA) constitutes a long-standing diagnostic problem resulting in equivocal histopathological diagnoses. There is therefore a need for additional molecular markers. To identify molecular differences between FTC and FTA, we analyzed the gene expression microarray data of 52 follicular neoplasms. We also performed a meta-analysis involving 14 studies employing high throughput methods (365 follicular neoplasms analyzed). Based on these two analyses, we selected 18 genes differentially expressed between FTA and FTC. We validated them by quantitative real-time polymerase chain reaction (qRT-PCR) in an independe…

0301 basic medicinePathologyMicroarrayThyroid Glandlaw.inventionlawFollicular phaseGene expressionAdenocarcinoma Follicularfollicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysisSpectroscopyPolymerase chain reactionOligonucleotide Array Sequence Analysisfollicular thyroid cancerGeneral MedicineCANCERComputer Science ApplicationsGene Expression Regulation NeoplasticCARCINOMASFUSION ONCOGENEmicroarrayNEOPLASMSmedicine.medical_specialtyMOLECULAR MARKERSASPIRATIONBiologyCatalysisCLASSIFICATIONArticleInorganic Chemistry03 medical and health sciencesNODULESADENOMASmedicineBiomarkers TumorHumansRNA MessengerThyroid NeoplasmsPhysical and Theoretical ChemistryFollicular thyroid cancerMolecular BiologyGeneGene Expression ProfilingOrganic ChemistryThyroid adenomaACVRL1medicine.diseaseMODELmeta-analysis030104 developmental biologyfollicular thyroid adenomaMutationgene expressionInternational Journal of Molecular Sciences
researchProduct

Reprint of "EXOSOME LEVELS IN HUMAN BODY FLUIDS: A TUMOR MARKER BY THEMSELVES?"

2017

Despite considerable research efforts, the finding of reliable tumor biomarkers remains challenging and unresolved. In recent years a novel diagnostic biomedical tool with high potential has been identified in extracellular nanovesicles or exosomes. They are released by the majority of the cells and contain detailed molecular information on the cell of origin including tumor hallmarks. Exosomes can be isolated from easy accessible body fluids, and most importantly, they can at once provide with several biomarkers, with different levels of specificity. Recent clinical evidence shows that the levels of exosomes released into body fluids may by themselves represent a predictive/diagnostic of t…

0301 basic medicinePharmaceutical ScienceExosomesExosome03 medical and health sciencesProstate cancerTumor Biomarkers0302 clinical medicineMedicineHigh potentialTumor markerProstate cancerbusiness.industryFollow-upCancerExtracellular vesiclesEarly diagnosismedicine.diseaseMicrovesiclesBody fluids030104 developmental biologyClinical evidence030220 oncology & carcinogenesisImmunologyCancer researchbusinessBiomarkersEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

3D polymeric supports promote the growth and progression of anaplastic thyroid carcinoma.

2020

Abstract Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy that accounts for the majority of deaths from all thyroid cancers. ATC exhibits invasiveness and highly resistance to conventional therapies which include cytotoxic chemotherapy, the combination of BRAF and MEK inhibition and, more recently, immunotherapies, that have shown promising but still limited results. A growing knowledge on ATC tumor biology is needed for developing more effective therapies with significant better survival. Researchers have begun to utilize 3D models to culture cancer cells for in vitro studies. In this work, C643 ATC cell line was cultured on polymeric scaffolds with high-interconnecte…

0301 basic medicinePolymersBiophysicsMalignancyStem cell markerThyroid Carcinoma AnaplasticBiochemistryMetastasis03 medical and health sciences0302 clinical medicineCancer stem cellCell Line TumormedicineBiomarkers TumorHumansDoxorubicin3D tumor model Anaplastic thyroid carcinoma Doxorubicin Polymeric scaffold Stem cell markersMolecular BiologyThyroid cancerCell ShapeCell ProliferationTissue Scaffoldsbusiness.industryThyroidCell Biologymedicine.disease030104 developmental biologymedicine.anatomical_structureDoxorubicin030220 oncology & carcinogenesisCancer cellCancer researchDisease ProgressionNeoplastic Stem Cellsbusinessmedicine.drugBiochemical and biophysical research communications
researchProduct

Population genetic structure and milk production traits in Girgentana goat breed

2017

The aim of this work was to evaluate the genetic status of the Girgentana goat, an endangered breed from Sicily (Italy), using microsatellite markers. Furthermore, as the main purpose of the Girgentana breed is milk production, quantitative milk traits were investigated, including fatty acid profile. Molecular data from CSN1S1, CSN2, CSN1S2, and CSN3 casein genes were also used to infer haplotypes. A total of 264 individuals were collected. Samples of Maltese (n = 41) and Derivata di Siria (n = 33) goat breeds were also used to understand the genetic relationship among breeds. Test-day records for milk production were collected to determine daily milk yield, fat, protein, casein, lactose, a…

0301 basic medicinePopulationBiologyGenetic correlationSettore AGR/17 - Zootecnica Generale E Miglioramento Genetico03 medical and health scienceschemistry.chemical_compoundAnimal scienceCaseinGenetic variabilityLactoseeducationeducation.field_of_studymilk yield and gross composition.business.industrymicrosatellite marker0402 animal and dairy sciencefood and beveragescasein genes; microsatellite markers; milk yield and gross composition.; Food Science; Animal Science and Zoology04 agricultural and veterinary sciences040201 dairy & animal scienceBreedBiotechnologycasein gene030104 developmental biologyGenetic distancechemistryAnimal Science and ZoologybusinessSomatic cell countFood ScienceAnimal Production Science
researchProduct

The expression and prognostic relevance of programmed cell death protein 1 in tongue squamous cell carcinoma

2020

Background Programmed cell death protein 1 (PD‐1) is an immune checkpoint receptor which plays an important role in a patient´s immune responses to microbial and cancer antigens. It is expressed in tumor infiltrating lymphocytes (TILs) with many different malignancies. The aim of the study was to evaluate PD‐1 expression and its prognostic value in tongue cancer. Methods The data of tongue squamous cell carcinoma (TSCC) patients (N=81) treated in Tampere University Hospital between 1999‐2013 was used. Control data consisted of patients with non‐malignant tongue mucous membrane lesions (N=48). The formalin‐fixed paraffin‐embedded samples were stained immunohistochemically and scanned via dig…

0301 basic medicineProgrammed Cell Death 1 Receptorbiomarkkerittongue squamous cell carcinomaLYMPHOCYTES0302 clinical medicineImmunology and AllergyEPIDEMIOLOGYReceptorDISSECTIONAged 80 and over11832 Microbiology and virologyLIGAND 1 PD-L1Mucous membranemolekyylitGeneral MedicineMiddle AgedCANCER3. Good healthTongue Neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisimmunohistochemistryCarcinoma Squamous CellSURVIVALImmunohistochemistrysyöpätauditProgrammed cell death protein 1 (PD-1)Microbiology (medical)AdultAdolescentPathology and Forensic Medicine03 medical and health sciencesYoung AdultImmune systemAntigenTonguePOOR-PROGNOSISmedicineBiomarkers TumorHumansNECKAgedmolecular markerbusiness.industryHUMAN-PAPILLOMAVIRUSCancerennusteetprogrammed cell death protein 1 (PD‐1)medicine.diseaseImmune checkpoint030104 developmental biologyCancer researchT-CELLSprognosis3111 Biomedicinebusiness
researchProduct

Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long…

2020

Introduction: Surgical procedure is the treatment of choice in early stage I lung adenocarcinoma. However, a considerable number of patients experience recurrence within the first 2 years after complete resection. Suitable prognostic biomarkers that identify patients at high risk of recurrence (who may probably benefit from adjuvant treatment) are still not available. This study aimed at identifying methylation markers for early recurrence that may become important tools for the development of new treatment modalities. Methods: Genome-wide DNA methylation profiling was performed on 30 stage I lung adenocarcinomas, comparing 14 patients with early metastatic recurrence with 16 patients with …

0301 basic medicinePulmonary and Respiratory MedicineOncologyLung adenocarcinomamedicine.medical_specialtyLung NeoplasmsADNAdenocarcinoma of LungMethylation profilingmedicine.disease_causeMethylation03 medical and health sciences0302 clinical medicinePrognostic markerPLUTInternal medicineBiomarkers TumorHumansMedicineddc:610Promoter Regions Geneticbusiness.industryHazard ratioPromoterMethylationDNADNA MethylationPrognosismedicine.diseaseLong non-coding RNA030104 developmental biologyDifferentially methylated regionsOncology030220 oncology & carcinogenesisIncRNACàncer de pulmóBiomarker (medicine)AdenocarcinomaRNA Long NoncodingNeoplasm Recurrence LocalLung cancerbusinessCarcinogenesisMetilació
researchProduct